

Edgar Filing: INTERLEUKIN GENETICS INC - Form 8-K

INTERLEUKIN GENETICS INC  
Form 8-K  
May 31, 2002

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): MAY 29, 2002  
-----

INTERLEUKIN GENETICS, INC.  
-----

(Exact name of registrant as specified in its charter)

DELAWARE ----- (State or other jurisdiction of incorporation)	000-23413 ----- (Commission File Number)	94-3123681 ----- (IRS Employer Identification No.)
---	---	---

135 BEAVER STREET, WALTHAM, MA 02452 ----- (Address of principal executive offices)	(Zip Code)
---	------------

Registrant's telephone number, including area code: (781) 398-0700  
-----

ITEM 5. OTHER EVENTS.  
-----

On May 29 2002, Interleukin Genetics, Inc. publicly disseminated a press release announcing a clinical study with researchers at UnitedHealth Group's Center for Health Care Policy & Evaluation to determine the influence of genetic markers on an individual's response to anti-IL-1 and anti-TNF $\alpha$  therapy in adults with rheumatoid arthritis.

The information contained in the press release is incorporated herein by reference and filed as Exhibit 99.1 hereto.

Edgar Filing: INTERLEUKIN GENETICS INC - Form 8-K

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.  
-----

(c) Exhibit.

99.1 Press Release dated May 29, 2002.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTERLEUKIN GENETICS, INC.  
-----

(Registrant)

Date: May 30, 2002

/s/ Fenel M. Eloi  
-----

Fenel M. Eloi, Vice President, Chief Operating  
Officer and Chief Financial Officer

3

EXHIBIT INDEX  
-----

Exhibit  
Number  
-----

Description  
-----

99.1 Press Release dated May 29, 2002

4